Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 2/20 | 0.41 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CETP | P11597 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26217525 | 0.89 | HSD17B1 (0.43) | HSD17B1HSD17B2MTNR1AMTNR1BNPC1 | |
| SCHEMBL26264793 | 0.84 | BCL2A1 (0.46) | TP53POLBMAPTLMNAALDH1A1 | |
| SCHEMBL26264792 | 0.83 | LMNA (0.49) | MTNR1AMTNR1BNPC1RAB9ATP53 | |
| SCHEMBL26264796 | 0.83 | ALDH1A1 (0.45) | NPC1RAB9ATP53POLBMAPT | |
| SCHEMBL26264794 | 0.79 | CETP (0.44) | TP53POLBMAPTCETPLMNA | |
| SCHEMBL26264800 | 0.79 | L3MBTL1 (0.47) | RAB9AMAPTLMNA | |
| SCHEMBL26264805 | 0.77 | POLQ (0.44) | MAPTLMNAALDH1A1 | |
| SCHEMBL26222016 | 0.77 | ALDH1A1 (0.45) | NPC1RAB9ATP53POLBMAPT | |
| SCHEMBL26264797 | 0.74 | LMNA (0.43) | MTNR1AMTNR1BNPC1RAB9ATP53 | |
| SCHEMBL26263915 | 0.73 | HSD17B1 (0.43) | HSD17B1HSD17B2NPC1RAB9ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11806323-B2 | Topical anesthetics | PTC Innovations, LLC (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230285332-A1 | TOPICAL ANESTHETICS | PTC INNOVATIONS LLC (US) | 2023-09-14 | — | — | US | disclosed |
| WO-2023172603-A1 | ANESTHETIC COMPOUNDS AND METHODS OF MAKING AND USING SAME TO TREAT OR PREVENT PAIN SYMPTOMS | PTC Innovations, LLC (US) | 2023-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285332-A1 | TOPICAL ANESTHETICS | OR10J3, ALKBH3, CHRM3 | HSD17B1 4147/4885HSD17B2 4093/4885MTNR1A 984/4885 |
| US-11806323-B2 | Topical anesthetics | OR10J3, ALKBH3, CHRM3 | HSD17B1 4060/4885HSD17B2 4024/4885MTNR1A 1035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.